New EU Auvergne-Rhone-Alpes partnership to boost French textile sector
Home to over 800 companies with a skilled workforce of 18,000, the region generates €3.5 billion in revenue a year, making Auvergne-Rhone-Alpes the French leader in technical and functional textiles.
Dedicated to improving competitiveness and sustainability in the textiles industry, the new partnership focuses on regional strategies to strengthen skills development and tackle workforce shortages in the sector, an official release said.
An EU Pact for Skills partnership in France's Auvergne-Rhone-Alpes region will improve competitiveness and sustainability in the textiles industry. It focuses on regional strategies to strengthen skills development and tackle workforce shortages in the sector. It will help textile companies anticipate and adapt to evolving skills needs driven by economic, technological and societal changes.
The Pact for Skills is one of the flagship actions of the European Skills Agenda. It aims at supporting public and private organisations with upskilling and reskilling, so they can thrive through green and digital transitions.
The textile sector faces challenges that threaten its sustainability and competitiveness. One of the primary concerns is the sector's ability to stay competitive amidst the rise of energy costs, limited access to raw materials and the increasing demands of the ecological transition.
In addition, the sector faces work-related challenges, with 63 per cent of companies struggling to fill key roles. An ageing workforce, shifting skills demands and limited training capacity have intensified the challenge.
The Regional Skills Partnership will create a resilient and adaptable textile workforce that can respond to ongoing changes. It will help textile companies anticipate and adapt to evolving skills needs driven by economic, technological and societal changes.
In addition, the partnership will promote lifelong learning through apprenticeships and will support professional integration and inclusion across the sector.
It will also work to raise awareness of careers in textiles, attracting, guiding and retaining people through training programmes.
Together, these efforts will strengthen the sector's resilience and competitiveness. These ambitions are driven by key objectives to boost the sector's adaptability and European reach.
Finally, the partnership will position Auvergne-Rhone-Alpes as a leading European textile region by contributing to the TCLF Skills Alliance, a collaborative initiative focused on enhancing skills development within the textile, clothing, footwear and leather (TCLF) industries in Europe, and EU initiatives like the TCLF SkillBridge.
To meet its goals, the partnership will design new training frameworks and transform existing training courses to meet companies' needs. These will be focused on sustainability-related objectives.
It will also monitor emerging trends like adopting artificial intelligence.
Fibre2Fashion News Desk (DS)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
19 minutes ago
- Business Standard
Relais & Châteaux adds Jaipur's Sarvato, eyes growth in new states
French luxury hotel association Relais & Châteaux added 52-seater Sarvato restaurant at City Place, Jaipur as its newest member from India. The association which is a collection of individually owned boutique properties often equated to the Michelin star guide of restaurants, presently has seven other properties under its umbrella in the country, underscoring the exclusivity and rigorous criterion required for a property to become part of the elite association. 'We are very picky and have high standards that we want our members to adhere to. I believe that details – like the thickness of paper, the placement of a switch – are what creates emotion in a customer and hence quality,' Laurent Gardinier, president, Relais & Châteaux told Business Standard in an exclusive interaction. Sarvato champions slow cooking and remains open only from September to April every year. The ultra-luxury boutique restaurant has been added after an extensive, year-long survey which the association undertook in India to identify potential additions to the over 70 year old association, which includes only over 600 properties worldwide. 'Luxury is not about serving world cuisine like spaghetti Bolognese and hamburgers to guests, but about being able to create an emotion through an authentic, local experience where they are staying,' he added. Gardinier, who was in India on a two-day trip, said the network is evaluating properties to add to its Indian portfolio. 'There has been a big explosion of the Indian market in terms of a destination, and we also see now that it's a little bit easier to come to India—like the visa process easing considerably, and modernisation in infrastructure. So, we have identified 40 properties in the country that could potentially become part of the network,' he said. According to Gardinier, for a property to qualify, it must have a heritage connection, around 40–50 rooms, be located at a desirable site, and offer a fine gastronomic experience. The Relais & Châteaux designation is a prestigious accolade for independent hoteliers and restaurateurs worldwide. The association has also identified underrepresented states such as Uttar Pradesh, Himachal Pradesh, and Rajasthan as priorities for expansion. With most individual members aged around 45, Relais & Châteaux reported a cumulative sales volume of €3.2 billion in 2024, up 8 per cent from 2023. Of this, 42.1 per cent came from food and beverage activity, nearly matching the 49 per cent generated by hotel rooms. In India, Sri Lanka, and Thailand, however, hotel rooms represent a larger share of sales—52 per cent in 2024—while food and beverage accounts for only 33 per cent. It is this gastronomic gap that the association now aims to address. Sarvato becomes the eighth Relais & Châteaux property in India, joining Suján Sher Bagh near Ranthambore National Park, which captures the spirit of a 1920s safari; The Malabar House, an art hotel in Cochin that celebrates Kerala's cultural history as a passage between East and West; and Masque, a Mumbai-based restaurant that blends heritage and innovation, among others. Among destinations gaining traction, 82 per cent of travel activity by Indian, Thai, and Sri Lankan clients is concentrated in Europe—most notably in France (28 per cent), Italy (23 per cent), Switzerland (9 per cent), and the UK (6 per cent).
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Leapfrogging the world: China's rise in EVs, green energy and biotech
In the global race for technological supremacy, the spotlight has long fallen on Silicon Valley or Europe's innovation hubs. But behind the scenes, China is not merely catching up, it is rapidly emerging as a global frontrunner, spearheading transformative progress across electric vehicles (EVs), renewables, and biotechnology. Fuelled by state-backed strategies, relentless innovation, and manufacturing muscle, China's ascent is not just changing industries, it is redefining the world's technological future. EV boom: How China became the world's largest electric vehicle market China now controls the world's largest EV market, selling over 11 million units annually and accounting for more than 50 per cent of global EV sales. Companies like BYD, NIO, XPeng, and Li Auto have aggressively expanded beyond Chinese borders, with BYD overtaking Tesla in total global EV sales in 2025. China's dominance in EV exports is equally notable. In 2024, it shipped out 1.2 million EVs—surpassing Japan to become the world's top automobile exporter. Once mocked for low-cost knock-offs, Chinese EVs now compete on both price and advanced tech in Europe, Southeast Asia, and North America. According to Bloomberg, China's EV sales reached 11 million units in 2024, capturing nearly two-thirds of the global market, compared to 17 per cent in Europe and just 7 per cent in the US. In Q1 2025 alone, Chinese EV sales rose 55 per cent to 1.64 million units, outpacing Europe's 28 per cent (574,000) and the US' 18 per cent (301,000). What explains China's electric vehicle dominance? At the heart of China's EV power lies control over battery technology. With 70 per cent of global EV production and two domestic giants, CATL and BYD, supplying 55 per cent of the world's batteries, China enjoys unmatched battery pricing and efficiency. Fierce local competition has driven breakthrough innovations, bringing battery costs below $100/kWh for lithium iron phosphate (LFP) batteries, reaching price parity with combustion engines, a milestone still out of reach in the West. China's vertically integrated supply chain accounts for 75 per cent of lithium-ion battery production, and dominates cobalt/lithium refining and cathode/anode materials. In contrast, European and US supply chains remain fragmented and face 20 per cent higher production costs. Technologies like battery-swap stations and vehicle-to-grid (V2G) integration are giving Chinese EVs a technological and cost advantage. How state strategy fuels China's EV ecosystem Under the 'Made in China 2025' plan, China has built a powerful EV ecosystem through massive subsidies, sustained infrastructure investment, and long-term supply chain planning. It already boasts 20 times more public EV chargers than the US, and four times as many as Europe. China's renewable energy dominance breaks all global records In the renewables sector, China's lead is even more formidable. As of mid-2025, its solar capacity stood at 887 GW, with wind at 521 GW. The country invested $625 billion in clean energy in 2024 alone, according to Reuters. By comparison, the US has just 239 GW of solar, and the EU a combined 540 GW of wind and solar. In 2024, China added 445 GW of new renewables, 60 per cent of global additions. It builds three out of every four solar and wind installations worldwide and is on track to exceed its 2030 emissions targets ahead of schedule. China also manufactures over 80 per cent of the world's solar panels and dominates every stage of the solar and battery supply chain. Economies of scale, vertical integration, and heavy subsidies let Chinese producers outprice global competitors. Chinese biotech: From copycats to cutting-edge drug developers China's biotechnology sector is undergoing a dramatic transformation. Once known for generics, Chinese drugmakers are now innovating at scale. Bloomberg's analysis of Norstella data shows that China had over 1,250 novel drug candidates in 2024, closing in on the US (1,440) and far ahead of the EU. Back in 2015, that number was just 160. Chinese biopharma companies, once burdened with quality concerns, are increasingly earning approvals and partnerships with global regulators and pharma majors. By 2024, Chinese firms accounted for 31 per cent of all innovative drug pipelines globally, second only to the US. Policy reforms and returning scientists reshape Chinese biotech China's shift began in 2015 with sweeping reforms to its drug regulatory framework, accelerating approvals, enforcing global data standards, and encouraging repatriation of overseas-trained researchers. Coupled with the Made in China 2025 strategy, these efforts triggered a biotech investment boom. By 2024, China had overtaken the EU in expedited approvals from the FDA and EMA. Faster drug approvals and global impact Take Legend Biotech's cell therapy for blood cancer—marketed by Johnson & Johnson. It not only outpaced a US-made rival but also secured expedited review in multiple markets. Although Chinese firms still focus on refining existing therapies more than inventing new ones, their innovation pipeline is expanding. Of the world's top 50 companies with the most innovative drug candidates between 2020 and 2024, 20 are Chinese—up from just five in the prior five-year period. Jiangsu Hengrui, once a generic drugmaker, now leads globally in the number of new drug candidates added. Global pharma giants race to license Chinese innovations Western pharma majors are rushing to partner with Chinese firms: > Akeso Inc. licensed its cancer drug to Summit Therapeutics for $500 million upfront, seen as China biotech's 'DeepSeek moment' > Pfizer signed a record $1.2 billion upfront deal in May 2025 with 3SBio Inc. for a cancer therapy > Merck, AstraZeneca, and Roche have all snapped up Chinese drug assets According to DealForma, such high-value licensing deals are growing in both number and value. China's clinical trial edge: speed and scale A key advantage for Chinese biotech is speed. Thanks to vast patient pools and centralised hospitals, trial recruitment in China happens twice as fast as in the US. Lower costs allow companies to run multiple clinical trials simultaneously, boosting success odds. Since 2021, China has led the world in new clinical trial starts, ahead of the US, per GlobalData. However, challenges remain. The FDA still requires multinational data, limiting the use of China-only trials for US approvals. US reacts to China's biotech rise with new policy anxieties As US-China tensions rise, China's biotech progress has drawn concern in Washington. A congressional report warned that the US may cede leadership in another strategic domain. Policymakers are calling for tighter export restrictions and faster domestic drug approval processes. The China model: What makes its rise hard to replicate Across EVs, renewables, and biotechnology, China's strategy follows a clear pattern: centralised industrial planning, global supply chain dominance, technology at scale, and relentless execution speed. For the West, the question is no longer if China can lead in innovation, but how soon, and how far.
Economic Times
30 minutes ago
- Economic Times
Gold rate, silver price predictions: Experts predict short-term prices target
Gold price and silver rate are likely to have support from a number of factors including Donald Trump tariffs. Tired of too many ads? Remove Ads Gold Price Prediction Tired of too many ads? Remove Ads Gold prices firmed on Tuesday as concerns over the global trade war fuelled demand for safe-haven assets, while investors awaited a key U.S. inflation reading. Spot gold rose 0.6 per cent to $3,361.99 per ounce. U.S. gold futures were up 0.4 per cent to $3,371.30. The U.S. dollar was down 0.1 per cent, making gold cheaper for buyers holding other is edging higher as bulls look to take advantage of the dollar that's a touch lighter today, said Han Tan, chief market analyst at Gold enjoys plenty of supportive factors, from expectations for Fed rate cuts, U.S. President Donald Trump's tariff threats, as well as persistent geopolitical and economic risks, Han Tan European Union on Monday accused the U.S. of resisting efforts to strike a trade deal and warned of countermeasures if no agreement is reached to avoid the punishing tariffs Trump has threatened to impose starting on August escalated his trade war on Saturday, announcing a 30 per cent tariff on most EU and Mexican imports, after issuing similar warnings to other trading the U.S. consumer price index (CPI) report, due at 1230 GMT, could give investors more guidance on the Federal Reserve's policy path.U.S. consumer prices likely picked up in June, potentially marking the start of a long-anticipated, tariff-induced increase in inflation that has left the Fed cautious about resuming rate cuts. Markets currently anticipate 48 basis points worth of rate cuts by the end of this year, starting in spot silver gained 0.4 per cent to $38.28 per ounce, after hitting its highest level since September 2011 on Monday. If the current gold to silver price ratio is maintained, at gold prices above $3,440/oz, we will see silver above $40/oz, said WisdomTree commodities strategist Nitesh rose 0.8 per cent to $1,373.85, while palladium rose 0.2 per cent to $1,195.59.A1. Elsewhere, spot silver gained 0.4 per cent to $38.28 per ounce, after hitting its highest level since September 2011 on Monday.A2. Spot gold rose 0.6 per cent to $3,361.99 per ounce. U.S. gold futures were up 0.4 per cent to $3,371.30.
